香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 本 公 告 乃 應 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）之 要 求 並 根 據 聯 交 所 證 券 上 市 規 則（「上市規則」）第13.10條而作出。 謹此提述近日有關Cardiovalve Ltd.（杭州啓明醫療 器 械 股 份 有 限 公 司（「本公司」） 的全資附屬公司）與MTH IP, L.P.（本公司的合營企業）於美國特拉華州地區法院對 Edwards Lifesciences Corp.及Edwards Lifesciences LLC提起專利侵權訴訟的新聞文章。 經 本 公 司 作 出 在 有 關 情 況 下 屬 合 理 的 查 詢 後，本 公 司 確 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 於 二 零 二 六 年 一 月 十 四 日，Cardiovalve Ltd.與MTH IP, L.P.就美國第385號專利於美 國特拉華州地區法院對Edwards提 起 專 利 侵 權 訴 訟（「訴 訟」），指 控Edwards的核心產 品PASCAL Precision經導管瓣膜修復系統侵犯Cardiovalve Ltd.所持有的美國第385號 專利。 由於訴訟仍處於初步階段，進一步詳情（包括可能索償金額）仍須視乎訴訟結果而定。 本公司將根據香港聯合交易所有限公司證券上市規則的規定於適當時候就訴訟的 任何實質進展作出進一步公告。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 杭州啓明醫療器械股份有限公司 執行董事 林浩昇先生 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份 ...

Core Viewpoint - The company announced a patent infringement lawsuit filed by its wholly-owned subsidiary Cardiovalve Ltd. and joint venture MTH IP, L.P. against Edwards Lifesciences Corp. and Edwards Lifesciences LLC in the U.S. District Court for Delaware [1] Group 1 - The lawsuit pertains to alleged patent infringement related to medical devices [1] - The company has conducted reasonable inquiries and confirmed that it is not aware of any information that needs to be disclosed to prevent the company's securities from appearing in a false market [1] - The company asserts compliance with Listing Rule 13.09(2) and Section XIVA of the Securities and Futures Ordinance regarding disclosure obligations [1]

Core Viewpoint - The company, Qiming Medical-B (02500.HK), has filed a patent infringement lawsuit against Edwards Lifesciences Corp. and Edwards Lifesciences LLC through its wholly-owned subsidiary, Cardiovalve Ltd., in the U.S. District Court for Delaware [1] Company Summary - Qiming Medical-B has a market capitalization of HKD 1.491 billion and ranks 17th in the medical device II industry [1] - The company has a Return on Equity (ROE) of -26.56%, significantly lower than the industry average of -4.82% [1] - The company's operating revenue stands at HKD 427 million, compared to the industry average of HKD 1.201 billion, placing it 18th in the industry [1] - The net profit margin is -72.02%, while the industry average is -19.02%, ranking 26th [1] - The gross profit margin is 73.74%, which is higher than the industry average of 53.75%, ranking 2nd [1] - The company's debt ratio is 33.77%, compared to the industry average of 29.81%, ranking 21st [1] Industry Summary - There has been low attention from investment banks towards Qiming Medical-B, with no ratings given in the past 90 days [1]

Core Viewpoint - The announcement highlights a patent infringement lawsuit filed by Cardiovalve Ltd., a wholly-owned subsidiary of the company, against Edwards Lifesciences Corp. and Edwards Lifesciences LLC in the U.S. District Court for Delaware [1] Group 1 - The lawsuit is a result of a partnership between Cardiovalve Ltd. and MTH IP, L.P., which is a joint venture of the company [1] - The company has conducted reasonable inquiries and confirmed that it is not aware of any information that needs to be disclosed to prevent the company's securities from appearing in a false market [1] - There are no insider information disclosures required under Listing Rule 13.09(2) and Part XIVA of the Securities and Futures Ordinance [1]

Core Viewpoint - The company, Qiming Medical-B (02500), has announced a patent infringement lawsuit filed by its wholly-owned subsidiary, Cardiovalve Ltd., and its joint venture, MTH IP, L.P., against Edwards Lifesciences Corp. and Edwards Lifesciences LLC in the U.S. District Court for the District of Delaware [1]. Group 1 - The lawsuit pertains to allegations of patent infringement against Edwards Lifesciences [1]. - The company has conducted reasonable inquiries and confirmed that it is not aware of any information that needs to be disclosed to prevent its securities from appearing misleading in the market [1]. - The company asserts compliance with the listing rules and securities and futures regulations regarding the disclosure of insider information [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 根據上市規則第13.10條作出之公告 本 公 告 乃 應 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）之 要 求 並 根 據 聯 交 所 證 券 上 市 規 則（「上市規則」）第13.10條而作出。 謹此提述近日有關Cardiovalve Ltd.（杭州啓明醫療 器 械 股 份 有 限 公 司（「本公司」） 的全資附屬公司）與MTH IP, L.P.（本公司的合營企業）於美國特拉華州地區法院對 Edwards Lifesciences Corp.及Edwards Lifesciences LLC提起專利侵權訴訟的新聞文章。 經 本 公 司 作 出 在 有 關 情 況 下 屬 合 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The pharmaceutical and biotechnology index decreased by 0.68% this week, underperforming the CSI 300 index by 0.11 percentage points, ranking 19th in industry performance [12] - The healthcare sector has shown significant growth, with the medical services sub-sector increasing by 16.04% year-to-date, while traditional Chinese medicine has the lowest growth at 1.86% [17][19] - The J.P. Morgan Health Conference highlighted the strategic advancements of top global pharmaceutical companies, with over 20 Chinese firms participating, indicating a trend towards overseas collaboration in innovative drugs [34] Summary by Sections Market Review - The pharmaceutical index has risen by 7.08% from the beginning of 2026 to January 16, outperforming the CSI 300 index by 4.88 percentage points, ranking 8th in industry performance [12] - The medical services sub-sector has the highest year-to-date growth at 16.04%, while the lowest is traditional Chinese medicine at 1.86% [19] Individual Stock Performance - In the A-share market, 206 out of 478 pharmaceutical stocks rose, with the top five performers being Baolait (up 48.76%), Hualan Biological (up 32.72%), and Tianzhihang (up 27.67%) [23] - In the Hong Kong market, 59 out of 116 pharmaceutical stocks increased, with Ark Health leading at 51.66% growth [26] Industry News and Policies - The sixth batch of national high-value medical consumables procurement was opened on January 13, with 202 companies winning bids for 440 products [29] - Medtronic announced a strategic partnership with Precision Neuroscience to develop integrated solutions combining their technologies [29] - Boston Scientific plans to acquire Penumbra for approximately $14.5 billion, enhancing its portfolio in peripheral vascular interventions [30] Weekly Insights - The medical services sector's strong performance is attributed to positive revenue growth, with medical commercial and services sectors showing year-on-year revenue increases of 0.56% and 3.99%, respectively [33] - The J.P. Morgan Health Conference served as a significant platform for discussing trends in drug development and investment strategies, with a focus on AI and international collaborations [34]

Group 1 - The core viewpoint of the article highlights that Qiming Medical-B (02500.HK) experienced a significant intraday increase of over 14%, with a current rise of 7.99%, reaching a price of 3.65 HKD per share [1] - The trading volume for Qiming Medical-B amounted to 26.2799 million HKD [1]

Core Viewpoint - The article highlights that Qiming Medical-B (02500) has initiated a patent infringement lawsuit against Edwards Lifesciences in the U.S., marking a significant step in the company's legal strategy to protect its intellectual property rights and enhance its competitive position in the global medical device market [1]. Group 1: Company Actions - Qiming Medical's subsidiary Cardiovalve has filed a lawsuit in the U.S. District Court of Delaware against Edwards, alleging that its PASCAL Precision transcatheter valve repair system infringes on Cardiovalve's U.S. Patent No. 10,702,385 [1]. - This legal action follows Qiming Medical's previous victory in July 2025, where it successfully upheld the validity of its US'385 patent against Edwards [1]. Group 2: Industry Implications - Analysts view this lawsuit as a proactive measure by Qiming Medical to defend its innovations, representing a milestone for Chinese medical device companies in leveraging a robust intellectual property system for global market competition [1].